WPCT.L - Woodford Patient Capital Trust plc

LSE - LSE Delayed price. Currency in GBp
74.10
0.00 (0.00%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous close74.10
Open73.69
Bid0.00 x 0
Ask0.00 x 0
Day's range73.51 - 74.17
52-week range0.74 - 74.17
Volume1,111,674
Avg. volume52,581
Market cap612.807M
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Is it finally time to invest in Woodford Patient Capital Trust plc?
    Fool.co.uk7 days ago

    Is it finally time to invest in Woodford Patient Capital Trust plc?

    Why I’ve come out surprisingly (for me) bullish on the prospects for Woodford patient Capital Trust plc (LON: WPCT).  

  • Should you buy Neil Woodford stock Circassia Pharmaceuticals after today’s price rise?
    Fool.co.uklast month

    Should you buy Neil Woodford stock Circassia Pharmaceuticals after today’s price rise?

    Here's why Circassia Pharmaceuticals plc (LON: CIR) might be a better bet than Woodford Patient Capital Trust plc (LON: WPCT).

  • Reuterslast month

    Woodford-backed biotech Prothena plunges as key drug fails

    Shares in Prothena (PRTA.O), a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial. As a result, Prothena is discontinuing development of the antibody-based medicine for the condition. The news is a win for short sellers who have targeted the stock but a fresh setback for Woodford, one of Britain's best-known fund managers.

  • Reuters - UK Focuslast month

    Woodford-backed biotech Prothena plunges as key drug fails

    Shares (Berlin: DI6.BE - news) in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial. As a result, Prothena is discontinuing development of the antibody-based medicine for the condition. The news is a win for short sellers who have targeted the stock but a fresh setback for Woodford, one of Britain's best-known fund managers.

  • Reuters - UK Focuslast month

    BUZZ-Woodford Patient Capital Trust takes Prothena hit

    ** Shares in Woodford Patient Capital Trust down 4.8 pct, second-biggest faller in the FTSE mid-cap index ** Stock hit by news key early stage pharma holding Prothena , in which the trust holds an 8.56 ...

  • Why I’d shun Woodford Patient Capital Trust and buy this super investment trust
    Fool.co.uk2 months ago

    Why I’d shun Woodford Patient Capital Trust and buy this super investment trust

    Harvey Jones can't understand the appeal of the woeful Woodford Patient Capital Trust (LON: WPCT) when investors could buy this investment trust flyer instead.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes